Hairy cell leukemia 2018: Update on diagnosis, risk-stratification, and treatment.

Published in: American journal of hematology (2017)

It is based on the use of BRAF inhibitors associated or not with MEK inhibitors, recombinant immunoconjugates targeting CD22 or BCR inhibitors.

Keyphrases